CinCor is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. CinCor’s focus is on cardiovascular, metabolic and kidney diseases. CinCor’s lead program is CIN-107, a novel aldosterone synthase inhibitor.